Department of Molecular Cell Biology and Immunology, VU University Medical Center, 1007 MB, Amsterdam, The Netherlands.
J Neuroinflammation. 2012 Jun 20;9:133. doi: 10.1186/1742-2094-9-133.
The sphingosine 1-phosphate (S1P) receptor modulator FTY720P (Gilenya®) potently reduces relapse rate and lesion activity in the neuroinflammatory disorder multiple sclerosis. Although most of its efficacy has been shown to be related to immunosuppression through the induction of lymphopenia, it has been suggested that a number of its beneficial effects are related to altered endothelial and blood-brain barrier (BBB) functionality. However, to date it remains unknown whether brain endothelial S1P receptors are involved in the maintenance of the function of the BBB thereby mediating immune quiescence of the brain. Here we demonstrate that the brain endothelial receptor S1P5 largely contributes to the maintenance of brain endothelial barrier function.
We analyzed the expression of S1P5 in human post-mortem tissues using immunohistochemistry. The function of S1P5 at the BBB was assessed in cultured human brain endothelial cells (ECs) using agonists and lentivirus-mediated knockdown of S1P5. Subsequent analyses of different aspects of the brain EC barrier included the formation of a tight barrier, the expression of BBB proteins and markers of inflammation and monocyte transmigration.
We show that activation of S1P5 on cultured human brain ECs by a selective agonist elicits enhanced barrier integrity and reduced transendothelial migration of monocytes in vitro. These results were corroborated by genetically silencing S1P5 in brain ECs. Interestingly, functional studies with these cells revealed that S1P5 strongly contributes to brain EC barrier function and underlies the expression of specific BBB endothelial characteristics such as tight junctions and permeability. In addition, S1P5 maintains the immunoquiescent state of brain ECs with low expression levels of leukocyte adhesion molecules and inflammatory chemokines and cytokines through lowering the activation of the transcription factor NFκB.
Our findings demonstrate that S1P5 in brain ECs contributes to optimal barrier formation and maintenance of immune quiescence of the barrier endothelium.
鞘氨醇 1-磷酸(S1P)受体调节剂 FTY720P(Gilenya®)可显著降低神经炎症性疾病多发性硬化症的复发率和病变活动。尽管其大部分疗效已被证明与通过诱导淋巴细胞减少来免疫抑制有关,但有人认为其许多有益作用与改变内皮细胞和血脑屏障(BBB)功能有关。然而,迄今为止,尚不清楚大脑内皮细胞 S1P 受体是否参与维持 BBB 的功能,从而介导大脑的免疫静止。在这里,我们证明大脑内皮细胞受体 S1P5 在很大程度上有助于维持大脑内皮细胞屏障功能。
我们使用免疫组织化学分析了人死后组织中 S1P5 的表达。通过激动剂和慢病毒介导的 S1P5 敲低在培养的人脑内皮细胞(EC)中评估 S1P5 在 BBB 中的功能。对大脑 EC 屏障的不同方面的后续分析包括形成紧密的屏障、BBB 蛋白的表达以及炎症和单核细胞迁移的标志物。
我们表明,在体外培养的人脑 EC 上,通过选择性激动剂激活 S1P5 可增强屏障完整性并减少单核细胞的跨内皮迁移。这些结果通过在脑 EC 中基因沉默 S1P5 得到了证实。有趣的是,这些细胞的功能研究表明,S1P5 强烈有助于脑 EC 屏障功能,并为特定的 BBB 内皮特征的表达提供了基础,例如紧密连接和通透性。此外,S1P5 通过降低转录因子 NFκB 的激活来维持脑 EC 的免疫静止状态,使白细胞黏附分子和炎症趋化因子和细胞因子的表达水平降低。
我们的研究结果表明,脑 EC 中的 S1P5 有助于最佳的屏障形成和维持屏障内皮的免疫静止。